Compare IDYA & FRMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDYA | FRMI |
|---|---|---|
| Founded | 2015 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.2B |
| IPO Year | 2019 | 2025 |
| Metric | IDYA | FRMI |
|---|---|---|
| Price | $36.76 | $4.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 8 |
| Target Price | ★ $52.86 | $26.13 |
| AVG Volume (30 Days) | 661.4K | ★ 14.0M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $218,710,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $201.05 | $120.76 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3024.43 | N/A |
| 52 Week Low | $26.05 | $4.43 |
| 52 Week High | $42.68 | $32.39 |
| Indicator | IDYA | FRMI |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 36.48 |
| Support Level | $34.74 | N/A |
| Resistance Level | $38.37 | $7.65 |
| Average True Range (ATR) | 1.28 | 0.30 |
| MACD | -0.28 | -0.01 |
| Stochastic Oscillator | 29.25 | 2.03 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Fermi Inc develops next-generation private electric grids that deliver redundant power at gigawatt scale to support next-generation intelligence and AI compute. It combines cutting-edge technology with a deep bench of world-class, multidisciplinary leaders with a combined 25 GW of experience to create one of the world's 17 GW next-gen private grids, helping ensure America's energy and AI dominance. The behind-the-meter Project Matador campus is expected to integrate the nation's combined-cycle natural gas project, one of the clean, new nuclear power complexes in America, utility grid power, solar power, and battery energy storage, to support hyperscale AI and computing.